Rocket Lab’s Valuation Debate: A Clash of Wall Street Titans

Rocket Lab USA US7731221062

The investment case for Rocket Lab USA has become a battleground for opposing analyst views, highlighting the central question of how to value a stock that has surged over 260% in the past year. The core of the debate hinges on whether this impressive rally is built on speculative momentum or is now supported by tangible contracts and a solid operational foundation.

Rocket Lab shares have more than tripled in value over the last twelve months, recently closing at $90.76. This places the stock just shy of its 52-week high of $91.80. This dramatic ascent has set the stage for a direct clash between two major financial institutions, Morgan Stanley and KeyBanc Capital Markets, who issued contradictory ratings within a two-day period.

On Friday, Morgan Stanley provided a significant bullish catalyst by upgrading Rocket Lab from "Equal-Weight" to "Overweight." The firm's analysts also raised their price target substantially, from $67 to $105 per share. Their optimism is rooted in a robust outlook for the space and satellite sector projected for 2026, anticipating increased launch frequencies and maturing commercial demand. They view Rocket Lab as a "strategically important" player with credible long-term growth potential, capable of expanding beyond mere launch services.

This upgrade directly countered a more cautious stance taken by KeyBanc just one day prior. On Thursday, KeyBanc downgraded Rocket Lab from "Overweight" to "Sector Weight." Their rationale centered on valuation, arguing that near-term growth drivers—including recent contract wins—are already largely reflected in the current share price. Following the rapid rally, KeyBanc sees a balanced risk-reward profile, though it continues to acknowledge the company's operational quality and leading market position.

Strategic Contracts and Operational Execution

Amid the valuation debate, Rocket Lab's business fundamentals show significant strength. Operationally, the company reported a record 21 successful Electron launches in 2025, reinforcing its reliability in the small satellite segment. Strategically, a landmark $816 million contract from the Space Development Agency (SDA) stands out. This agreement, the largest in company history, involves developing and building 18 satellites for the Tranche 3 Tracking Layer. It underscores Rocket Lab's strategic pivot from a pure-play launch provider to a vertically integrated space company delivering complete satellite platforms.

Insider Activity and Technical Indicators

Recent transactions by company insiders have also drawn market attention. Board member Merline Saintil sold a total of 108,500 shares on January 13th and 14th, transactions valued at approximately $9.4 million at prices between $86 and $90 per share. While such sales are often interpreted as cautionary signals, the market's reaction on Friday was overwhelmingly dominated by the bullish Morgan Stanley note. High trading volume and price gains suggested institutional investors were focusing on the long-term growth narrative.

From a technical perspective, the stock is trading at a significant premium: approximately 42% above its 50-day moving average and nearly 90% above its 200-day moving average. A Relative Strength Index (RSI) reading of 85 indicates an overbought condition, and the stock's volatility remains high at around 90% (annualized, 30-day).

The Neutron Factor and Upcoming Catalysts

A critical component of Rocket Lab's long-term valuation is the development of its medium-lift "Neutron" rocket, positioned to compete directly with SpaceX's Falcon 9. Successfully entering this lucrative payload segment would substantially expand the company's addressable market. The program is targeting a first flight in 2026, and its development timeline carries significant risk; any progress updates or delays are likely to trigger notable stock price movements. Investors are effectively tying the current premium valuation to the expectation of Neutron's on-schedule technical and operational execution.

The next major test for the stock will be the upcoming quarterly earnings report, scheduled for February 26th. This release is expected to provide more concrete details on the Neutron development schedule and revenue recognition from the SDA contract backlog. The financials and guidance will be scrutinized to determine whether the bullish $105 price target from Morgan Stanley aligns with fundamental business progress, or if KeyBanc's more cautious valuation perspective will gain traction.